Liminatus Pharma (LIMN) Stock Is Trending Overnight — Here’s Why it Spiked Over 30% in After-Hours Session

Liminatus Pharma, Inc. (NASDAQ: LIMN ) shares are trending on Wednesday night. 15 in after-hours trading after Liminatus amended and restated its merger agreement with InnocsAI LLC, a cell-therapy developer. Revised Structure Fast-Tracks Closing The announcement, made after Wednesday’s market close, said the revised structure allows the deal to close before obtaining shareholder approval, with closing now expected on Thursday.

99% of outstanding shares under Nasdaq rules, and non-voting convertible preferred stock. 20 per common share, implying a total deal value of about $320 million. Equity holders will also receive contingent value rights worth 20% of future net proceeds from certain strategic transactions. CEO Chris Kim called the merger a “transformational step” in the company’s strategy to build a diversified oncology biotechnology company.

10. 38%. 89%. LIMN is currently positioned close to its annual low.

The stock’s sharp decline and weak positioning point to continued pressure, highlighting elevated risk and the need for clearer signs of recovery before investor confidence can return. 87 million shares of common stock outstanding, as of May 14. 99%. Edge Stock Rankings indicate that LIMN has a negative price trend across all time frames.

com Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published editors. Read Also: Vimeo Owner Bending Spoons (BSP) Stock Is Trending After Hours: Here's What You Should Know